Galderma Group
CHF 160.55Change from previous close: −0.16%Absolute change: −CHF 0.25
At a glance
- Revenue growth
- +18.04%
- 2025 vs 2024
- Net income growth
- +165.37%
- 2025 vs 2024
- Net margin
- 11.7%
- 2024: 5.2%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|
| Total assets | 13,526 | 13,393 | 12,877 | 12,617 | 12,579 | 12,471 | — |
| Current assets | 2,649 | 2,437 | 1,910 | 1,843 | 1,793 | 1,616 | — |
| Cash and equivalents | 839 | 780 | 458 | 457 | 385 | 368 | — |
| Receivables | 1,088 | 1,062 | 865 | 905 | 928 | 765 | — |
| Inventory | 650 | 525 | 502 | 403 | 414 | 420 | — |
| Net property, plant and equipment | 789 | 744 | 672 | 577 | 550 | 529 | — |
| Goodwill | 5,129 | 5,129 | 5,129 | 5,129 | 5,129 | 5,129 | — |
| Other intangible assets | 4,521 | 4,639 | 4,751 | 4,829 | 4,867 | 4,923 | — |
| Long-term investments | 1.0 | 3.0 | 3.0 | 1.0 | 3.0 | 10.0 | — |
| Current liabilities | 2,133 | 2,055 | 1,750 | 1,528 | 1,498 | 1,571 | — |
| Accounts payable | 820 | 799 | 631 | 571 | 550 | 557 | — |
| Long-term debt | 2,503 | 2,579 | 2,700 | 2,636 | 2,822 | 4,748 | — |
| Total debt | — | 2,754 | 2,847 | — | — | — | — |
| Total liabilities | 5,311 | 5,244 | 5,147 | 4,827 | 4,947 | 7,102 | — |
| Total equity (incl. minority) | 8,215 | 8,149 | 7,730 | 7,790 | 7,632 | 5,369 | — |
| Retained earnings | 6,798 | 6,347 | 5,901 | 5,676 | 5,469 | -901 | — |